was significantly decreased ($p<0.001$) from 36.8 (14.9) at baseline, to reach 12.5 (10.3) after 9 months of treatment, with a reduction of 64%. In a similar pattern, the mean HAQ-DI score was significantly decreased ($p<0.001$) from 1.5 (0.7) at baseline to reach 0.6 (0.6) after 9 months of treatment, with a reduction of 57%. Figures 1 and 2 show changes in both CDAI and HAQ-DI scores throughout the study.

Figure 1: CDAI Score at Baseline, Month 3 and Month 9

Figure 2: HAQ-DI at Baseline, Month 3 and Month 9

Figure 3: Disease severity at Baseline, Month 3 and Month 9

Abstract Figure 3. shows that disease severity was significantly improved ($p<0.001$) throughout the study, and 19.1% of patients were at remission after 9 months of treatment.

Twenty-three adverse events (AEs) were reported in 20 patients (5%) throughout the study period; most frequently, increased hepatic enzymes (6 cases, 1.5%), increased swollen/tender joint count (2 cases, 0.5%), decreased white blood cell count (2 cases, 0.5%), and abdominal discomfort (2 cases, 0.5%). None of the reported AEs were related to treatment with leflunomide.

Conclusion: Results from this study demonstrate that leflunomide may offer an effective, tolerable and safe treatment –whether used as a monotherapy or in combination with other csDMARDs– in Egyptian patients with active RA.

REFERENCES

- [1] Ailred A, Emery P. Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis. Expert opinion on pharmacotherapy. 2001;2(1):125-137.
- [2] El Sayed A. Clinical efficacy and safety of leflunomide in Egyptian patients with active rheumatoid arthritis: CLEAR interim results. The open rheumatology journal. 2018;12(1):323-331.

Acknowledgement: Thanks to all Investigators: A Abd El Hamid, A Darwish, AE Hilal, A Elgerby, AF Abou Gamal, A Labib, AS Omar, D Abd El Mohsen, D Fayez, E Abda, F Elshabacy, M El Shehaly, M El Tayel, M El Wakd, M Mortada, N Mohannad, R Abd El Kader, S El Bakry, S Refaat, and S Zaki. Data management, statistical analysis, site monitoring activities, and editorial support were provided by DATA Clin CRO and funded by EVAPHARMA.

Disclosure of Interests: Adel Elsayed Grant/research support from: This study was funded by EVAPHARMA.

DOI: 10.1136/annrheumdis-2019-eular.4595

AB0421

METHOTREXATE COMPLIANCE AMONG PATIENTS WITH CHRONIC INFLAMMATORY DISEASE OR CONNECTIVE TISSUE DISEASE

Elisabeth FILHOL¹, Charlotte Hua¹, Francoise Flaisler², Cédric Lukas³, Bernard Combe³, Jacques Morel³, Cecile Gaujoux-Viala¹. ¹Nîmes University Hospital, Montpellier University, Nîmes, France; ²Nîmes University Hospital, Nîmes, France; ³Lapeyronie hospital, Montpellier University, Montpellier, France

Background: Methotrexate (MTX) is widely used in rheumatology. About 30% of patients receiving MTX do not respond. One of the explanations could be poor adherence.

Objectives: The purpose of this study was to assess adherence and to identify predictive factors influencing it.

Methods: 188 patients with MTX for at least 3 months (rheumatoid arthritis (RA), peripheral spondyloarthritis (PS), psoriatic arthritis (PA), lupus, Sjögren's Syndrome (SS)) were enrolled between May 2017 and May 2018. Each patient completed a questionnaire including socio-demographic data, disease and MTX characteristics, 4-question Morisky, rheumatism activity scores including DAS 28, quality of life (EQ-5D), fibromyalgia (FIRST), anxiety and depression (HADS), catastrophism (PCS-CF), coping (WCC-R) and whether or not to participate in a therapeutic education program.

Results: 188 were recruited, of which 75% were women, with a mean age of 61.4 +/- 13.24 years: RA (77.12%), PS (7.98%), PA (10.11%), lupus (2.66%) and SS (2.13%). 68.6% were observant, versus 31.4% unobservant minor (28.2%) or major (3.2%) patients. In multivariate analysis, two models were performed and found a poor adherence in case of depression OR: 3.120 [1.051; 9.354], catastrophism OR: 3.974 [1.119; 14.108], anti-CCP antibodies OR: 4.019 [1.277; 12.653] in RA patients and depression OR: 2.715 [1.237; 5.963], absence of comorbidities OR: 2.309 [1.085; 4.915] with all rheumatism.

Conclusion: Some modifiable factors such as depression and catastrophism were associated with the risk of non-adherence with MTX. It is important to consider depression and catastrophism when taking care of our patients to improve adherence and avoid therapeutic escalations.

Disclosure of Interests: Elisabeth FILHOL: None declared, Charlotte Hua: None declared, Francoise Flaisler: None declared, Cédric Lukas: None declared, Bernard Combe Consultant for: Abbvie, Bristol-Myers Squibb, Gilead, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Roche-Chugai, Sanofi, UCB, Jacques Morel: None declared, Cecile Gaujoux-Viala Consultant for: Speaking and/or consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Merck-Serono, Medac, Nordic Pharma, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB Pharma., Speakers bureau: Speaking and/or consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Merck-Serono, Medac, Nordic Pharma, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB Pharma.

DOI: 10.1136/annrheumdis-2019-eular.4682

AB0422

ACHIEVEMENT OF PATIENT ACCEPTABLE SYMPTOM STATE (PASS) IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BARICITINIB

Cristina Garufi, Francesca Spinelli, Fulvia Ceccarelli, Ilaria Duca, Silvia Mancuso, Cristiano Alessandri, Guido Valesini, Fabrizio Conti. Policlinico Umberto I, Rheumatology, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Roma, Italy, Roma, Italy

Background: Baricitinib, a newly approved drug for the treatment of patients with moderate to severe rheumatoid arthritis (RA), is a selective inhibitor of Janus kinase 1 and 2. In a patient-centered care, patient-reported outcomes (PROs) are really helpful to better evaluate the disease activity and the response to therapy. Between them, Patient Acceptable Symptom State (PASS) is defined as the highest level of symptoms beyond which patients consider themselves well [1], and consists of a single question with dichotomized answer (yes or no): "Considering all the different ways your disease is affecting you, if you would stay in this state for the next months, do you consider that your current state is satisfactory?". In randomized controlled trials baricitinib showed significant improvement of pain, fatigue, tiredness and assessment of disease [2].

Objectives: The aim of the present study was to investigate the effect of baricitinib on PASS one month from the beginning of therapy. Further aim was to quantify the time patients needed to reach an acceptable state of health and determine the clinical variables associated with PASS.

Methods: Patients affected by RA according to 2010 ACR criteria, starting treatment with baricitinib as clinically indicated, were consecutively enrolled; PASS was determined after 1 month of treatment (T1); days to

achieve PASS were estimated at T1; activity indices were calculated after 1 month of therapy and correlated with PASS.

Results: Thirty-four RA patients were enrolled (age median-IQR 58-16 years; disease duration median-IQR 144-138 months; DAS-28 median-IQR 5.09-1.92). After 1 month of therapy, 30 of 34 patients achieved PASS, of which 73% in the first 2 weeks of treatment (days to achieve PASS median-IQR 12-22) (figure). At T1, patients achieving PASS, compared to those who did not, reported less pain (median VAS 30/100 vs 72/100, $p=0.025$), a better global assessment of disease (median 40/100 vs 72/100, $p=0.023$), lower CDAI (median 12 vs 31, $p=0.048$), SDAI (median 12.8 vs 33.95, $p=0.011$) and DAS-28 (median 3.67 vs 5.54, $p=0.082$). 10 out of 30 PASS positive patients (33%) achieved a DAS-28 low-disease activity or remission at T1 vs 0% of the PASS negative cohort ($p=0.169$). Age, disease duration and number of previous bDMARDs did not significantly differ between the two subgroups.

Conclusion: Baricitinib was able to induce an acceptable state of health in about 90% of patients after the first month of therapy. The prompt effect of baricitinib on pain and fatigue could partially explain the rapid achievement of PASS, as shown by the decrease of VAS and improvement of the global assessment of disease.

REFERENCES

- [1] Maksymowych WP, et al. Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis. *Arthritis Rheum* 2007
- [2] Schiff, et al. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. *Arthritis Res Ther*. 2017

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.7244

AB0423

CHANGES IN DISEASE ACTIVITY, PAIN, GLOBAL HEALTH AND PHYSICAL FUNCTION AFTER SWITCHING FROM ORAL TO SUBCUTANEOUS METHOTREXATE: RESULTS OF THE SIX-MONTH OBSERVATIONAL PROSPECTIVE STUDY IN CROATIA

Simeon Grazio¹, Dijana Perković², Nadica Laktašić Žerjavić³, Marija Glasnović⁴, Frane Grubišić¹, Ana Gudelić Gračanin⁵, Željka Kolak⁶, Helena Kolar Mitrović³, Jadranka Morović-Vergles⁵, Porin Perić⁷, Petra Šimac², Iva Žagar³, Ines Doko¹.

¹University Hospital Centre Sestre milosrdnice, Dpt. of Rheumatology, Physical Medicine and Rehabilitation, School of Medicine University of Zagreb, Zagreb, Croatia; ²University Hospital Centre Split, Dpt. of Internal Medicine, School of Medicine University of Split, Split, Croatia; ³University Hospital Centre Zagreb, Dpt. of Rheumatic Diseases and Rehabilitation, School of Medicine University of Zagreb, Zagreb, Croatia; ⁴University Hospital Centre Osijek, Dpt. of Internal Medicine, School of Medicine University of Osijek, Osijek, Croatia; ⁵University Hospital Dubrava, Dpt. of Internal Medicine, School of Medicine University of Zagreb, Zagreb, Croatia; ⁶General County Hospital Vinkovci, Division of Physical Medicine and Rehabilitation, Vinkovci, Croatia; ⁷University Hospital Centre Zagreb, Dpt. of Rheumatic Diseases and Rehabilitation, School of Medicine University of Zagreb, Zagreb, Croatia

Background: In rheumatoid arthritis (RA) and psoriatic arthritis (PsA) methotrexate (MTX) is usually the first choice in the treatment strategy.

Bioavailability of oral MTX reaches plateau in doses ≥ 15 mg weekly, and this is the reason of its lower clinical efficacy.

Objectives: The objective of this observational longitudinal study was to evaluate the changes in disease activity, intensity of pain, global health, and physical function when switching from oral (P.O.) to subcutaneous (S.C.) MTX in patients with RA and peripheral form of PsA.

Methods: Forty-eight consecutive patients (79.2% women) with established diagnosis of RA (77.1%) and peripheral PsA were enrolled from the outpatient clinics in six centres in Croatia. Median age was 61 (39-79) years, and the median of disease duration was 120 (3-528) months. Data were collected at baseline (T0) including retrospective data collection from the previous 3 months (on P.O. MTX), at day 90 (± 10 days) (T1) and at day 180 (± 10 days) (T2) for the previous periods, both of them during S.C. MTX treatment. Dose of MTX remained stable during the study. Domains of interest were Disease Activity Score on 28 joints measured using ESR (DAS28-ESR), level of pain, Patient's Global Health Assessment (PtGHA) and Physician's Global Health Assessment (PhGHA) were measured on horizontal 100 mm VAS, while physical function was measured by Health Assessment Questionnaire – Disability Index (HAQ-DI).

Results: Out of 48 patients 41 patients were switched to S.C. MTX monotherapy and 7 to S.C. MTX in combination with another csDMARD. At T1 40 patients were on S.C. MTX monotherapy and 8 on S.C. MTX in combination with another DMARD, and at T2 39 patients were on S.C. MTX monotherapy, 4 on S.C. MTX in combination with another DMARD, 1 on another DMARD and 4 were lost to follow-up. DAS28 showed trend of decrease from 4.9 at baseline to 4.6 at T1 and 4.2 at T2. Analysis of transition of patients according to DAS28 EULAR criteria has shown that percentage of patients with low disease activity has raised from 4.3% at T0, to 21.7% at T1, and 24.3% at T2, while percentage of patients with high disease activity has declined from 38.3% at T0 to 21.7% at T1 and 13.5% at T2. Recommendation for prednisone therapy > 7.5 mg/QD had 12.5% patients at T0 and T1, and only 6.8% patients at T2. There was a significant decrease in adjusted mean values for level of pain (-1.46; 95%CI -1.55, -0.35), PtGHA (-1.12; 95%CI -1.50, -0.73) and PhGHA (-1.15; 95%CI -1.50, -0.80). HAQ-DI showed significant improvement during the 6-month follow-up (-0.25; 95%CI -0.32, -0.17).

Conclusion: Patients who switched from P.O. to S.C. MTX showed improvement in all observed parameters: decrease of disease activity, reduction of pain, better global health, and physical function. Results of our study are in line with previously published literature data.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.4961

AB0424

A RETROSPECTIVE STUDY OF ARTHROSCOPIC SYNOVECTOMY FOR REFRACTORY KNEE ARTHRITIS COMPLICATED WITH POPLITEAL CYST

peng.han¹, Jian Zhu², Jianglin Zhang², Feng Huang². ¹Chinese PLA General Hospital, Department of Rheumatology, Beijing, China; ²Chinese PLA General Hospital, Department of Rheumatology, Beijing, China

Background: Baker's cyst or popliteal cyst is the most common mass surrounding the knee joint that results from inflammatory knee arthritis. With increasing number of arthroscopic synovectomy performed for refractory knee arthritis annually, we aim to explore its value in baker's cyst treatment.^[1]

Objectives: To investigate the efficacy of arthroscopic synovectomy on refractory knee arthritis complicated with popliteal cyst.

Methods: A retrospective analysis of 153 patients (RA= 95, SpA= 58) with refractory knee arthritis, underwent knee arthroscopic synovectomy in our hospital from 2010 to 2017, was performed. Among them, 20 patients (RA= 16, SpA= 4) complicated with popliteal cyst. We compared the changes in inflammation makers, disease activity score, imaging manifestations, symptoms, the rate and the grading of popliteal cyst^[2] before and after the operation to evaluate the efficacy of knee arthroscopic synovectomy.^[3]

Results: Inflammation markers[ESR(49.42 $\pm$ 32.54 vs 24.46 $\pm$ 24.17, $P<0.001$), CRP(8.55 $\pm$ 16.43 vs 5.60 $\pm$ 22.45, $P<0.001$), Rheumatoid Factor(191.29 $\pm$ 373.72 vs 74.90 $\pm$ 158.31, $P<0.001$), DAS28 score(4.67 $\pm$ 1.25 vs 2.81 $\pm$ 1.23, $P<0.001$), knee joint discomfort score(5.2 $\pm$ 1.7 vs 1.9 $\pm$ 1.5, $P<0.001$) and the amount of knee joint effusion by ultrasound scanning ($P<0.05$) in 95 RA patients were significantly decreased compared to those before the operation; Inflammation markers[ESR(36.76 $\pm$ 28.71 vs 21.19 $\pm$ 9.79, $P<0.001$), CRP(21.19 $\pm$ 9.79 vs 3.36 $\pm$ 6.44, $P<0.001$), knee discomfort score (4.48 $\pm$ 1.06 vs 2.51 $\pm$ 1.54, $P<0.05$), back pain VAS score(2.74 $\pm$ 2.88 vs 1.56 $\pm$ 1.70, $P<0.001$), and the amount of knee joint effusion by ultrasound